GINKGO-PHARMA®
Pharmaceutical-grade Ginkgo biloba leaf.
European in-region cultivation for the EGb 761-type extract profile — 24% flavone glycosides, 6% terpene lactones. Addresses a pharmaceutical supply chain currently dominated by extra-EU sources.
Ginkgo leaf is the source material for one of the most established pharmaceutical phytochemical fractions globally — standardised extract of the EGb 761-type profile: 24% flavone glycosides, 6% terpene lactones. GINKGO-PHARMA® is the TEHNOFARM® programme for European in-region cultivation under documented agronomy, addressing a supply chain currently dominated by extra-EU sources.
Cultivation status
0.300 ha active plantation in Corbu, Donduşeni raion, north-eastern Moldova. Phytosanitary status confirmed bună (good) under ANSA Phytosanitary Act Nr. 0349968 of 17 September 2021 — visual control identified no quarantine-grade pests or pathogens. Cultivation phase: cultivar selection complete; propagation in progress under NORD NUC operational management.
Industrial alignment horizon
First commercial-volume leaf harvest projected from 2029, as the plantation reaches mature leaf-yield phase under the seven-year cultivation cycle characteristic of pharmaceutical-grade Ginkgo biloba. Stability and full analytical profile development continues across the cultivation period.
Partner portal
Detailed agronomic protocols, projected yield curves, and analytical specifications are available to qualifying partners through the partner portal at ginkgo.md.
Engagement
Pharmaceutical and nutraceutical industrial partners interested in advance discussion of supply alignment from 2029 forward: contact@tehnofarm.md. Subject line: GINKGO-PHARMA® inquiry.